Literature DB >> 1556093

Dynamics of interleukin-6 internalization and degradation in rat hepatocytes.

J E Nesbitt1, G M Fuller.   

Abstract

We have investigated the dissociation, internalization, and degradation of 125I-interleukin-6 (125I-IL-6) by primary rat hepatocytes. Temperature shift experiments following saturation binding of 125I-IL-6 to cell surface receptors in hepatocytes showed a rapid loss of surface-bound 125I-IL-6 (t1/2 = 15 min), concomitant with a rapid rise in internalized radiolabeled ligand. After reaching a maximum by 30 min at 37 degrees C, the level of internalized 125I-IL-6 decreased with time and appeared in the culture media in a non-trichloroacetic acid-precipitable (degraded) state. The addition of the lysosomotropic agent chloroquine inhibited this receptor-mediated degradation of IL-6 without affecting ligand internalization. Polyacrylamide gel electrophoresis analysis of internalized 125I-IL-6 confirms these results. Additionally, we show that the IL-6.IL-6 receptor complex is stable, and dissociation of these two molecular species occurs at a pH below 5.0. In contrast to published results, data presented in this study clearly indicate that IL-6 is rapidly internalized and degraded within hepatocytes by a receptor-mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1556093

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Internalization of the interleukin 6 signal transducer gp130 does not require activation of the Jak/STAT pathway.

Authors:  S Thiel; I Behrmann; E Dittrich; L Muys; J Tavernier; J Wijdenes; P C Heinrich; L Graeve
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

2.  The STAT3 beacon: IL-6 recurrently activates STAT 3 from endosomal structures.

Authors:  Christopher L German; Brian M Sauer; Charles L Howe
Journal:  Exp Cell Res       Date:  2011-05-18       Impact factor: 3.905

3.  Effect of the selective and non-selective cysteine protease inhibitors on the intracellular processing of interleukin 6 by HEPG2 cells.

Authors:  J V Peppard; A K Knap
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-09       Impact factor: 2.416

Review 4.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

Review 5.  Physiological and pathological roles of interleukin-6 in the central nervous system.

Authors:  D L Gruol; T E Nelson
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

Review 6.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

7.  In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.

Authors:  DE-Jun Guo; Jia-Shan Han; Yan-Song Li; Zeng-Shan Liu; Shi-Ying Lu; Hong-Lin Ren
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

8.  Phosphorylation and internalization of gp130 occur after IL-6 activation of Jak2 kinase in hepatocytes.

Authors:  Y Wang; G M Fuller
Journal:  Mol Biol Cell       Date:  1994-07       Impact factor: 4.138

9.  Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.

Authors:  M Schwabe; A T Brini; M C Bosco; F Rubboli; M Egawa; J Zhao; G L Princler; H F Kung
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

10.  Down-regulation of gamma interferon, tumor necrosis factor type I, interleukin 1 (IL-1) type I, IL-3, IL-4, and transforming growth factor beta type I receptors at the local site during the acute phase of Shigella infection.

Authors:  R Raqib; A A Lindberg; L Björk; P K Bardhan; B Wretlind; U Andersson; J Andersson
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.